Corneal Epithelial Stem Cells–Physiology, Pathophysiology and Therapeutic Options

Ruan, Yue; Jiang, Subao; Musayeva, Aytan; Pfeiffer, Norbert; Gericke, Adrian

doi:10.3390/cells10092302

Cited by 41 publications

(29 citation statements)

References 272 publications

(303 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these, the epithelium, the stroma, and the endothelium have a primary role in the drug/nanocarrier transport. Corneal epithelium is a five to seven-layered structure, composed of squamous, wing and basal cells [ 61 ]. Its lipophilic nature, and the existing intercellular tight junctions (zonula occludens) hinder the entry of hydrophilic substances and macromolecules [ 14 , 62 ].…”

Section: Eye Anatomy Barriers and Routes In Ocular Drug Deliverymentioning

confidence: 99%

Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms

Gugleva

Andonova

2023

Pharmaceuticals

View full text Add to dashboard Cite

Sufficient ocular bioavailability is often considered a challenge by the researchers, due to the complex structure of the eye and its protective physiological mechanisms. In addition, the low viscosity of the eye drops and the resulting short ocular residence time further contribute to the observed low drug concentration at the target site. Therefore, various drug delivery platforms are being developed to enhance ocular bioavailability, provide controlled and sustained drug release, reduce the number of applications, and maximize therapy outcomes. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) exhibit all these benefits, in addition to being biocompatible, biodegradable, and susceptible to sterilization and scale-up. Furthermore, their successive surface modification contributes to prolonged ocular residence time (by adding cationic compounds), enhanced penetration, and improved performance. The review highlights the salient characteristics of SLNs and NLCs concerning ocular drug delivery, and updates the research progress in this area.

show abstract

Section: Eye Anatomy Barriers and Routes In Ocular Drug Deliverymentioning

confidence: 99%

Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms

Gugleva

Andonova

2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…The corneal epithelium replenishes itself through adult stem cells (SC) located within the limbal palisades of Vogt. Regenerative therapies use different approaches to reestablish this cell population in limbal SC deficiency (LSCD), and historically, multiple cell replacement techniques have been developed [3][4][5] (Table 1). Since LSCD is an orphan disease, a major challenge is achieving adequate sample sizes for each technique as well as for comparative studies.…”

Section: Epitheliummentioning

confidence: 99%

Recent advances in cell-based regenerative therapies for corneal disease

Kaufman

Jun

2023

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Purpose of reviewWith limited access of more than half the world's population to corneal transplantation, regenerative medicine may represent a promising alternative. This review explores the main advancements achieved in cell-based therapies for corneal epithelium, stroma, and endothelium during 2021--2022. Recent findingsMultiple surgical techniques have been developed for epithelial limbal stem cell replacement. Recent studies aimed to gain greater understanding and characterization of these techniques. Though no clear superiority could be demonstrated, simple limbal epithelial transplantation seems to have the most clinical and cost effectiveness. For stromal disease, autologous adipose-derived stem cells have shown favorable results. For endothelial dysfunction, the validity of intracameral cultivated allogeneic endothelial cell injection and Descemetorrhexis without endothelial keratoplasty, as well as the benefits of adjunctive rho-associated kinase inhibitors, were emphasized. SummaryA plethora of innovative cell-based regenerative therapies for corneal diseases have been developed in past years. While recent literature solidifies our knowledge, most studies are still in preliminary or preclinical stages. Though showing great promise, these approaches will require larger studies with betterdefined endpoints to establish their benefits over currently available treatments.

show abstract

“…Currently, it is generally acknowledged that persistent postoperative ocular surface in ammation plays a leading role in the recurrence of pterygium [9][10][11] , while inhibiting in ammation can promote ocular surface repair and alleviate the ocular irritation symptoms [12][13] , and increase the success rate of surgery [14] .…”

Section: Introductionmentioning

confidence: 99%

Chinese Materia Medica preparation alleviates ocular surface inflammation after pterygium surgery

WANG

SONG

HAN³

et al. 2023

Preprint

View full text Add to dashboard Cite

AIM To investigate the effect of modified Chufeng Yisun Decoction on ocular surface inflammation after pterygium surgery.METHODS This prospective study included 60 patients with primary pterygium who underwent monocular surgery in the Ophthalmology Department of Bozhou Hospital of Traditional Chinese Medicine between January 2023 and March 2023 were included. The patients were randomly divided into study group and control group by computer RAND function, with 30 cases in each group. In the control group, 30 patients were treated with pranoprofen eye drops, tobramycin dexamethasone eye drops, and deproteinized calf blood extract eye gel after the surgery. In the study group, 30 patients were treated by oral modified Chufeng Yisun Decoction in addition to the treatments in the control group for 1 week. The changes of ocular irritation symptoms, ocular inflammatory signs, tear IL-6 level, and tear ferning test of patients in the two groups were assessed. SPSS 21 software was used for statistical analysis, and GraphPad Prism 9 software was used for plotting the graphs.RESULTS Compared with 1 d and 2 d after the surgery, the OISS in patients of both groups was significantly lower at 1 week after the surgery (P < 0.05). The OISS was not significantly different between 1 d and 2 d after the surgery in the control group (P > 0.05), but was significantly lower on 2 d after the surgery than 1 d after the surgery in the study group (P < 0.05). The OISS in the study group was significantly lower than in the control group at 2 d and 1 week after the surgery (P < 0.05). The OSI and tear IL-6 level were significantly lower at 1 week after the surgery than 1 d after the surgery in both groups (P < 0.05), and the OSI and tear IL-6 level were also significantly lower in the study group than in the control group at 1 week after the surgery (P < 0.05). The TFT was better in the study group than in the control group at 1 week after the surgery (P < 0.05).CONCLUSION The modified Chufeng Yisun Decoction has a better effect on improving the ocular surface inflammation after pterygium surgery than the use of anti-inflammatory eye drops only.

show abstract

Corneal Epithelial Stem Cells–Physiology, Pathophysiology and Therapeutic Options

Cited by 41 publications

References 272 publications

Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms

Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms

Recent advances in cell-based regenerative therapies for corneal disease

Chinese Materia Medica preparation alleviates ocular surface inflammation after pterygium surgery

Contact Info

Product

Resources

About